© 2024 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
8 Antiobesity Therapies to Watch Closely
November 08, 2024
Dual and triple incretin agonists continue to lead the new therapies in the antiobesity pipeline. Here is an at-a-glance update of their progress toward approval.
Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease
November 07, 2024
The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.
When is It Time to Refer? A Dermatologist Considers Atopic Dermatitis Treated in Primary Care
November 07, 2024
Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.
Nonsteroidal Topical Treatments for Eczema: A Product Snapshot with Mona Shahriari, MD
November 06, 2024
They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.
Agitation-Type Behavior Occurs Across the Spectrum of Alzheimer Disease Severity, Advises Expert
November 06, 2024
Agitation in Alzheimer disease is not limited to the later stages, geriatric psychiatrist George Grossberg, MD, explains; look for it across the spectrum.
FDA Pushes Back PDUFA Date 3 Months for Tapinarof, 1% Cream for Atopic Dermatitis in Adults and Children
November 05, 2024
The standard 3-month extension is required by the FDA to review what it considered a "major amendment" to the Organon sNDA, ie, new data from ADORING 3.
Agitation in Alzheimer Disease: A Behavioral Snapshot with Geriatric Psychiatrist George Grossberg, MD
November 05, 2024
Agitation is the most common disabling neuropsychiatric symptom experienced by individuals with Alzheimer dementia; Grossberg explains how common in this short interview.
Semaglutide 2.4 mg Reduces Risk for Hospitalization for Any Cause in Adults with CVD, Obesity
November 05, 2024
ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.
Semaglutide 2.4 mg: Shows Superior Improvement in Liver Fibrosis, MASH Resolution in Pivotal Phase 3 Trial
November 04, 2024
Novo Nordisk announced the topline findings from the pivotal ESSENCE trial and intends to file applications in early 2025 with US and EU regulators.
The RSV Vaccine Population was Narrowed for Good Reason, says Robert Hopkins, Jr, MD, Medical Director of the NFID
November 04, 2024
ACIP recommendations for the most appropriate older population for the RSV vaccine has shifted and the NFID medical director explains why.